Probiotix Health

Probiotix Health FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Probiotix Health (PBX.AQ) as of Nov 3, 2026 is 126.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 31.86 % — a change of 296.50% (higher).

FCF Conversion

126.33 %

YoY

296.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Probiotix Health is 2024 126.33 % . FCF Conversion Rate (FCF/EBITDA) of Probiotix Health was 2023 31.86 % . It decreases by 296.50% higher compared to the previous year.

The Probiotix Health FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
104.99 GBP
Jan 1, 2020
310.53 GBP
Jan 1, 2021
20.60 GBP
Jan 1, 2022
331.33 GBP
Jan 1, 2023
31.86 GBP
Jan 1, 2024
126.33 GBP
The Probiotix Health FCF Conversion history
YEARFCF ConversionYoY
126.33 %+296.50%
31.86 %-90.38%
331.33 %+1,508.06%
20.60 %-93.36%
310.53 %+195.76%
104.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Probiotix Health Stock analysis

What does Probiotix Health do? ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets. Probiotix Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Probiotix Health stock

FCF Conversion Rate (FCF/EBITDA) of Probiotix Health is 126.33 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Probiotix Health changed from 31.86 % to 126.33 %, representing a 296.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Probiotix Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Probiotix Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Probiotix Health

All Key Metrics — Probiotix Health